Molecular genetics of autosomal recessive polycystic kidney disease

Peter C Harris, Sandro Rossetti

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Autosomal recessive polycystic kidney disease (ARPKD) is a severe form of inherited childhood nephropathy (∼1:20,000 live births) characterized by fusiform dilatation of collecting ducts and congenital hepatic fibrosis. Up to 30% die as neonates due to respiratory insufficiency and the majority of surviving infants develop hypertension. Progression to end stage renal disease occurs in 20-45% of cases within 15 years but a proportion maintain renal function into adulthood where complications of liver disease predominate. The ARPKD disease gene, PKHD1, has recently been identified through analysis of an orthologous animal model, the PCK rat. PKHD1 is a large gene (∼470kb) with 67 exons from which multiple transcripts may be generated by alternative splicing. It is highly expressed in kidney, with lower levels in liver and pancreas. The ARPKD protein, fibrocystin (4074aa and 447kDa), is predicted to be an integral membrane, receptor-like protein containing multiple copies of an Ig-like domain (TIG). Fibrocystin is localized to the branching ureteric bud, collecting and biliary ducts, consistent with the disease phenotype, and often absent from ARPKD tissue. In common with other PKD-related proteins, fibrocystin is localized to the primary cilia of renal epithelial cells, reinforcing the link between ciliary dysfunction and cyst development. Screens of PKHD1 have revealed 119 different mutations of various types spread throughout the gene. Several ancestral changes have been described, some localized to specific geographic populations. The majority of patients are compound heterozygotes and preliminary genotype/phenotype studies associate two truncating mutations with severe disease. The complexities of PKHD1, marked allelic heterogeneity and high level of missense changes complicate gene-based diagnostics.

Original languageEnglish (US)
Pages (from-to)75-85
Number of pages11
JournalMolecular Genetics and Metabolism
Volume81
Issue number2
DOIs
StatePublished - Feb 2004

Fingerprint

Autosomal Recessive Polycystic Kidney
Molecular Biology
Kidney
Genes
Phenotype
Mutation
Proteins
Cilia
Alternative Splicing
Live Birth
Heterozygote
Respiratory Insufficiency
Chronic Kidney Failure
Cysts
Liver Diseases
Dilatation
Pancreas
Exons
Liver
Ducts

Keywords

  • ARPKD
  • Autosomal recessive polycystic kidney disease
  • Caroli's disease
  • Cilia
  • Congenital hepatic fibrosis
  • DHPLC
  • Fibrocystin
  • Genotype/ phenotype correlations
  • Mutation analysis
  • PKHD1

ASJC Scopus subject areas

  • Biochemistry
  • Genetics
  • Endocrinology, Diabetes and Metabolism

Cite this

Molecular genetics of autosomal recessive polycystic kidney disease. / Harris, Peter C; Rossetti, Sandro.

In: Molecular Genetics and Metabolism, Vol. 81, No. 2, 02.2004, p. 75-85.

Research output: Contribution to journalArticle

@article{2e0770fe4b17421cba8c856356a084d1,
title = "Molecular genetics of autosomal recessive polycystic kidney disease",
abstract = "Autosomal recessive polycystic kidney disease (ARPKD) is a severe form of inherited childhood nephropathy (∼1:20,000 live births) characterized by fusiform dilatation of collecting ducts and congenital hepatic fibrosis. Up to 30{\%} die as neonates due to respiratory insufficiency and the majority of surviving infants develop hypertension. Progression to end stage renal disease occurs in 20-45{\%} of cases within 15 years but a proportion maintain renal function into adulthood where complications of liver disease predominate. The ARPKD disease gene, PKHD1, has recently been identified through analysis of an orthologous animal model, the PCK rat. PKHD1 is a large gene (∼470kb) with 67 exons from which multiple transcripts may be generated by alternative splicing. It is highly expressed in kidney, with lower levels in liver and pancreas. The ARPKD protein, fibrocystin (4074aa and 447kDa), is predicted to be an integral membrane, receptor-like protein containing multiple copies of an Ig-like domain (TIG). Fibrocystin is localized to the branching ureteric bud, collecting and biliary ducts, consistent with the disease phenotype, and often absent from ARPKD tissue. In common with other PKD-related proteins, fibrocystin is localized to the primary cilia of renal epithelial cells, reinforcing the link between ciliary dysfunction and cyst development. Screens of PKHD1 have revealed 119 different mutations of various types spread throughout the gene. Several ancestral changes have been described, some localized to specific geographic populations. The majority of patients are compound heterozygotes and preliminary genotype/phenotype studies associate two truncating mutations with severe disease. The complexities of PKHD1, marked allelic heterogeneity and high level of missense changes complicate gene-based diagnostics.",
keywords = "ARPKD, Autosomal recessive polycystic kidney disease, Caroli's disease, Cilia, Congenital hepatic fibrosis, DHPLC, Fibrocystin, Genotype/ phenotype correlations, Mutation analysis, PKHD1",
author = "Harris, {Peter C} and Sandro Rossetti",
year = "2004",
month = "2",
doi = "10.1016/j.ymgme.2003.10.010",
language = "English (US)",
volume = "81",
pages = "75--85",
journal = "Molecular Genetics and Metabolism",
issn = "1096-7192",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Molecular genetics of autosomal recessive polycystic kidney disease

AU - Harris, Peter C

AU - Rossetti, Sandro

PY - 2004/2

Y1 - 2004/2

N2 - Autosomal recessive polycystic kidney disease (ARPKD) is a severe form of inherited childhood nephropathy (∼1:20,000 live births) characterized by fusiform dilatation of collecting ducts and congenital hepatic fibrosis. Up to 30% die as neonates due to respiratory insufficiency and the majority of surviving infants develop hypertension. Progression to end stage renal disease occurs in 20-45% of cases within 15 years but a proportion maintain renal function into adulthood where complications of liver disease predominate. The ARPKD disease gene, PKHD1, has recently been identified through analysis of an orthologous animal model, the PCK rat. PKHD1 is a large gene (∼470kb) with 67 exons from which multiple transcripts may be generated by alternative splicing. It is highly expressed in kidney, with lower levels in liver and pancreas. The ARPKD protein, fibrocystin (4074aa and 447kDa), is predicted to be an integral membrane, receptor-like protein containing multiple copies of an Ig-like domain (TIG). Fibrocystin is localized to the branching ureteric bud, collecting and biliary ducts, consistent with the disease phenotype, and often absent from ARPKD tissue. In common with other PKD-related proteins, fibrocystin is localized to the primary cilia of renal epithelial cells, reinforcing the link between ciliary dysfunction and cyst development. Screens of PKHD1 have revealed 119 different mutations of various types spread throughout the gene. Several ancestral changes have been described, some localized to specific geographic populations. The majority of patients are compound heterozygotes and preliminary genotype/phenotype studies associate two truncating mutations with severe disease. The complexities of PKHD1, marked allelic heterogeneity and high level of missense changes complicate gene-based diagnostics.

AB - Autosomal recessive polycystic kidney disease (ARPKD) is a severe form of inherited childhood nephropathy (∼1:20,000 live births) characterized by fusiform dilatation of collecting ducts and congenital hepatic fibrosis. Up to 30% die as neonates due to respiratory insufficiency and the majority of surviving infants develop hypertension. Progression to end stage renal disease occurs in 20-45% of cases within 15 years but a proportion maintain renal function into adulthood where complications of liver disease predominate. The ARPKD disease gene, PKHD1, has recently been identified through analysis of an orthologous animal model, the PCK rat. PKHD1 is a large gene (∼470kb) with 67 exons from which multiple transcripts may be generated by alternative splicing. It is highly expressed in kidney, with lower levels in liver and pancreas. The ARPKD protein, fibrocystin (4074aa and 447kDa), is predicted to be an integral membrane, receptor-like protein containing multiple copies of an Ig-like domain (TIG). Fibrocystin is localized to the branching ureteric bud, collecting and biliary ducts, consistent with the disease phenotype, and often absent from ARPKD tissue. In common with other PKD-related proteins, fibrocystin is localized to the primary cilia of renal epithelial cells, reinforcing the link between ciliary dysfunction and cyst development. Screens of PKHD1 have revealed 119 different mutations of various types spread throughout the gene. Several ancestral changes have been described, some localized to specific geographic populations. The majority of patients are compound heterozygotes and preliminary genotype/phenotype studies associate two truncating mutations with severe disease. The complexities of PKHD1, marked allelic heterogeneity and high level of missense changes complicate gene-based diagnostics.

KW - ARPKD

KW - Autosomal recessive polycystic kidney disease

KW - Caroli's disease

KW - Cilia

KW - Congenital hepatic fibrosis

KW - DHPLC

KW - Fibrocystin

KW - Genotype/ phenotype correlations

KW - Mutation analysis

KW - PKHD1

UR - http://www.scopus.com/inward/record.url?scp=0346040225&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0346040225&partnerID=8YFLogxK

U2 - 10.1016/j.ymgme.2003.10.010

DO - 10.1016/j.ymgme.2003.10.010

M3 - Article

VL - 81

SP - 75

EP - 85

JO - Molecular Genetics and Metabolism

JF - Molecular Genetics and Metabolism

SN - 1096-7192

IS - 2

ER -